Literature DB >> 29035048

Structural Sequencing of Oligopeptides Aided by 1H Iterative Full-Spin Analysis.

Wei Gao1,2, James B McAlpine1,2, Mary P Choules1,2, José G Napolitano1,3, David C Lankin1,3, Charlotte Simmler1,3, Ngoc Anh Ho4, Hanki Lee4, Joo-Won Suh4,5, Ian W Burton6, Sanghyun Cho2, Scott G Franzblau2, Shao-Nong Chen1,2,3, Guido F Pauli1,2,3.   

Abstract

This report describes an approach using 1H NMR iterative full-spin analysis (HiFSA) to extract definitive structural information on unknown peptides from 1D 1H NMR data. By comparing the experimental data and HiFSA fingerprint of a known analogue, it is possible to isolate the characteristic 1H subspectrum of the different amino acids and, thus, elucidate the structure of the peptide. To illustrate this methodology, a comprehensive analysis of five new anti-Mycobacterium tuberculosis peptides (2-6), all analogues of ecumicin (1), was carried out. The method was validated by demonstrating congruence of the HiFSA-based structures with all available data, including MS and 2D NMR. The highly reproducible HiFSA fingerprints of the new ∼1600 amu peptides were generated in this process. Besides oligo-peptides, the HiFSA sequencing approach could be extended to all oligomeric compounds consisting of chains of monomers lacking H-H spin-spin coupling across the moieties. HiFSA sequencing is capable of differentiating complex oligomers that exhibit minor structural differences such as shifted hydoxyl or methyl groups. Because it employs the basic and most sensitive 1D 1H NMR experiment, HiFSA sequencing enables the exploration of peptide analogues up to at least 2000 amu, even with basic contemporary spectrometers and when only sub-milligram amounts of isolates are available.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29035048     DOI: 10.1021/acs.jnatprod.7b00207

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  5 in total

1.  Quality Control of Therapeutic Peptides by 1H NMR HiFSA Sequencing.

Authors:  Mary P Choules; Jonathan Bisson; Wei Gao; David C Lankin; James B McAlpine; Matthias Niemitz; Birgit U Jaki; Scott G Franzblau; Guido F Pauli
Journal:  J Org Chem       Date:  2019-02-22       Impact factor: 4.354

2.  High-Resolution Structure of ClpC1-Rufomycin and Ligand Binding Studies Provide a Framework to Design and Optimize Anti-Tuberculosis Leads.

Authors:  Nina M Wolf; Hyun Lee; Mary P Choules; Guido F Pauli; Rasika Phansalkar; Jeffrey R Anderson; Wei Gao; Jinhong Ren; Bernard D Santarsiero; Hanki Lee; Jinhua Cheng; Ying-Yu Jin; Ngoc Anh Ho; Nguyen Minh Duc; Joo-Won Suh; Celerino Abad-Zapatero; Sanghyun Cho
Journal:  ACS Infect Dis       Date:  2019-05-03       Impact factor: 5.084

Review 3.  Quantum mechanical NMR full spin analysis in pharmaceutical identity testing and quality control.

Authors:  Prabhakar S Achanta; Birgit U Jaki; James B McAlpine; J Brent Friesen; Matthias Niemitz; Shao-Nong Chen; Guido F Pauli
Journal:  J Pharm Biomed Anal       Date:  2020-09-08       Impact factor: 3.935

Review 4.  Strategies in anti-Mycobacterium tuberculosis drug discovery based on phenotypic screening.

Authors:  Edyta M Grzelak; Mary P Choules; Wei Gao; Geping Cai; Baojie Wan; Yuehong Wang; James B McAlpine; Jinhua Cheng; Yingyu Jin; Hanki Lee; Joo-Won Suh; Guido F Pauli; Scott G Franzblau; Birgit U Jaki; Sanghyun Cho
Journal:  J Antibiot (Tokyo)       Date:  2019-07-11       Impact factor: 2.649

5.  In Vitro Profiling of Antitubercular Compounds by Rapid, Efficient, and Nondestructive Assays Using Autoluminescent Mycobacterium tuberculosis.

Authors:  Gauri S Shetye; Kyung Bae Choi; Chang-Yub Kim; Scott G Franzblau; Sanghyun Cho
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.